To ling pharmaceutical industry won the "2020 Chinese medicine heritage innovation enterprise"

Pharmaceutical Network February 8th, recently, "2020 (5th) Sina Pharmaceutical Annual General Review List" was officially announced, to Ling Pharmaceuticals won the "2020 Chinese medicine heritage innovation enterprise."
Withling Pharmaceuticals inherits the essence of the traditional Chinese traditional medicine culture, improves in succession, develops in inheritance, inherits and innovates the theory of Chinese medicine, and systematically constructs three theoretical frameworks for the study of diseases, which belong to the major theoretical originality.
With Ling Pharmaceuticals as the guide, the use of modern high-tech research and development, production of science and technology chinese medicine, to promote the industrialization of Chinese medicine development, products covering cardiovascular diseases, respiratory diseases, tumors, diabetes, nerves, urinary system diseases and other major diseases.
, the company has more than ten patents of Chinese medicine, of which 8 are listed in the national health insurance directory, 5 are national base drug species.
Among them, lianhua Qing plague, heart contact, ginseng heart capsule three varieties of annual sales of more than 1 billion yuan, even flowering plague is in the fight against the new crown pneumonia has played a major role in becoming a representative of the viral respiratory public health events of Chinese medicine.
Since its establishment in 1992, Toling Pharmaceuticals has always taken "inheriting innovation for the benefit of mankind" as its corporate purpose, and has achieved fruitful results in institutional innovation, theoretical innovation, scientific and technological innovation, product innovation, technological innovation, etc., and won six national science and technology awards.
among them, in January 2020, the project "Construction of Chinese Medicine's Pulse Theology and Guiding the Prevention and Control of Microvascular Lesions" completed by Hebei Yiling Medical Research Institute as the first main research unit won the first prize of the 2019 National Science and Technology Progress Award.
According to the introduction, under the background of the vigorous promotion of national policies, Toling Pharmaceuticals will further develop its research and development and production advantages, pass on the essence, keep positive innovation, promote the revitalization and development of Chinese medicine, accelerate the modernization, industrialization and internationalization of Chinese medicine, and contribute to the development of Chinese medicine.